Hi there!
We track 52,000+ AI startups and surface hidden job opportunities that never appear on LinkedIn. Tell us what you're looking for, our AI agent does the searching. It's free and you sign up using Google. Go explore!
Precede Biosciences
Precede Biosciences is a precision medicine company that has developed a first-in-class comprehensive epigenomic liquid biopsy platform. This platform profiles circulating chromatin and the DNA…
Precede Biosciences
Precede Biosciences is a precision medicine company that has developed a first-in-class comprehensive epigenomic liquid biopsy platform. This platform profiles circulating chromatin and the DNA…
TL;DR
What they do: Develop a comprehensive epigenomic liquid biopsy that profiles circulating chromatin and the DNA methylome from 1 mL of plasma to infer gene expression and pathway activity.
Customers / partners: Drug developers and academic researchers (platform offered as RUO service).
Funding signal: Series A (~$57M) in Oct 2023; announced Series B equity plus strategic credit facility (total $83.5M) in Jan 2026.
Origin: Founded from research begun at Dana-Farber Cancer Institute; incubated via 5AM Ventures' 4:59 Initiative.
Company Overview
Problem Domain
Precision medicine diagnostics; liquid biopsy for cancer and other diseases (e.g., multiple sclerosis) to inform drug development and clinical decision-making.
Industry
Biotechnology / Precision Diagnostics
Funding Track Record
57000000.00
Reported participation from Illumina Ventures, Bristol-Myers Squibb, Qatar Investment Authority, Osage University Partners, Binney Street Capital and others.
63500000.00
Announced alongside a $20,000,000 strategic non-dilutive credit facility; new investors named include Labcorp Venture Fund, UPMC Enterprises, Mirae Asset, 28 Capital, and Alexandria Venture Investments.
Investor Signal
“Includes strategic and corporate investors (e.g., Illumina Ventures, Bristol-Myers Squibb, Labcorp Venture Fund) alongside venture investors (e.g., 5AM Ventures).”